GDTC
CytoMed Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · SG
$0.86
−5.49%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 720.3K | 324.4K | 69.5K | — | — |
| Cost of Revenue | 4.9M | 68.0K | 17.1K | 4.4M | — |
| Gross Profit | (4.2M) | 256.4K | 52.4K | (4.4M) | — |
| Operating Expenses | |||||
| R&D Expense | 1.1M | 2.2M | 1.9M | — | 1.5M |
| SG&A Expense | 486.8K | 2.6M | 1.6M | — | 705.3K |
| General & Admin Expense | 453.7K | 2.6M | 1.6M | — | 705.3K |
| Selling & Marketing Expense | 33.0K | — | — | — | — |
| Other Expenses | — | 226.8K | 122.4K | — | 111.7K |
| Total Operating Expenses | 1.6M | 5.0M | 3.6M | — | 2.3M |
| Cost and Expenses | 6.4M | 5.1M | 3.7M | 4.4M | 2.3M |
| Operating Income (EBIT) | (5.7M) | (4.8M) | (3.6M) | (4.4M) | (2.3M) |
| Non-Operating | |||||
| Interest Income | 47.7K | 123.9K | 317.7K | 285.7K | 2.1K |
| Interest Expense | 15.6K | 20.9K | 20.3K | 51.3K | 125.2K |
| Net Interest Income | 31.7K | 103.0K | 297.4K | 234.4K | (123.1K) |
| Other Non-Op Income/Expense | 406.4K | 792.7K | 1.1M | 228.5K | (790.0K) |
| Non-Operating Income (excl Interest) | (199.9K) | (813.6K) | (1.1M) | (279.8K) | 664.8K |
| EBT (Pre-Tax Income) | (5.3M) | (4.0M) | (2.5M) | (4.1M) | (3.1M) |
| Income Tax Expense | — | — | — | 653.00 | 1.6K |
| Bottom Line | |||||
| Net Income | (5.3M) | (4.0M) | (2.5M) | (4.1M) | (3.1M) |
| Earnings from Cont. Ops | (5.3M) | (4.0M) | (2.5M) | (4.1M) | (3.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (5.3M) | (4.0M) | (2.5M) | (4.1M) | (3.1M) |
| Per Share | |||||
| Basic EPS | ($0.44) | ($0.34) | ($0.22) | ($0.39) | ($0.40) |
| Diluted EPS | ($0.44) | ($0.34) | ($0.22) | ($0.39) | ($0.40) |
| Revenue Per Share | $0.06 | $0.03 | $0.01 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 11.9M | 11.6M | 11.5M | 10.6M | 7.9M |
| Diluted Shares Outstanding | 11.9M | 11.6M | 11.5M | 10.6M | 7.9M |
| Profitability Metrics | |||||
| EBITDA | (4.8M) | (3.6M) | (2.2M) | (3.7M) | (2.6M) |
| D&A | 688.3K | 401.6K | 335.4K | 381.1K | 392.9K |
| EBIT | (5.5M) | (4.0M) | (2.5M) | (4.1M) | (3.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026